NewAmsterdam Pharma (NASDAQ:NAMS) Director John Smither Sells 1,600 Shares of Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director John Smither sold 1,600 shares of NewAmsterdam Pharma stock in a transaction on Friday, September 4th. The shares were sold at an average price of $25.32, for a total value of $40,512.00. Following the sale, the director directly owned 8,760 shares of the company’s stock, valued at $221,803.20. This represents a 15.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

NewAmsterdam Pharma Trading Down 11.1%

Shares of NASDAQ:NAMS traded down $2.84 during trading on Wednesday, reaching $22.79. The company had a trading volume of 2,317,939 shares, compared to its average volume of 1,058,457. The company has a fifty day moving average of $29.34 and a two-hundred day moving average of $31.45. The stock has a market capitalization of $2.72 billion, a P/E ratio of -10.55 and a beta of 0.09. NewAmsterdam Pharma Company N.V. has a 12 month low of $22.34 and a 12 month high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative return on equity of 34.81% and a negative net margin of 3,644.21%.The company had revenue of $3.70 million for the quarter, compared to the consensus estimate of $2.83 million. As a group, equities research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.82 earnings per share for the current year.

Analyst Ratings Changes

NAMS has been the topic of a number of research reports. Jefferies Financial Group reissued a “buy” rating and set a $45.00 price objective on shares of NewAmsterdam Pharma in a report on Monday, July 20th. Royal Bank Of Canada decreased their price target on shares of NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. BMO Capital Markets started coverage on shares of NewAmsterdam Pharma in a report on Monday, July 20th. They issued an “outperform” rating and a $58.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $52.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, NewAmsterdam Pharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.73.

Hedge Funds Weigh In On NewAmsterdam Pharma

Hedge funds have recently modified their holdings of the company. Bank of America Corp DE raised its stake in shares of NewAmsterdam Pharma by 84.4% during the first quarter. Bank of America Corp DE now owns 847,089 shares of the company’s stock valued at $27,115,000 after acquiring an additional 387,698 shares during the last quarter. Swedbank AB bought a new stake in shares of NewAmsterdam Pharma in the fourth quarter worth about $3,189,000. Legato Capital Management LLC increased its holdings in NewAmsterdam Pharma by 258.7% during the 4th quarter. Legato Capital Management LLC now owns 83,833 shares of the company’s stock valued at $2,941,000 after purchasing an additional 60,463 shares during the period. JTC Employer Solutions Trustee Ltd purchased a new position in NewAmsterdam Pharma during the 4th quarter valued at about $2,649,000. Finally, Artia Global Partners LP raised its position in NewAmsterdam Pharma by 158.6% during the 4th quarter. Artia Global Partners LP now owns 503,936 shares of the company’s stock valued at $17,678,000 after purchasing an additional 309,098 shares during the last quarter. Hedge funds and other institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.